HC Wainwright Issues Positive Estimate for argenex Earnings

argenex SE (NASDAQ:ARGX) – Investment analysts at HC Wainwright raised their FY2029 earnings per share estimates for shares of argenex in a research note issued on Tuesday, August 18th. HC Wainwright analyst D. Tsao now expects that the company will earn $56.38 per share for the year, up from their prior estimate of $53.47. HC Wainwright currently has a “Buy” rating and a $1,202.00 target price on the stock. The consensus estimate for argenex’s current full-year earnings is $29.04 per share. HC Wainwright also issued estimates for argenex’s FY2030 earnings at $76.63 EPS.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, topping analysts’ consensus estimates of $5.86 by $1.46. The company had revenue of $1.54 billion for the quarter, compared to analysts’ expectations of $1.45 billion. argenex had a return on equity of 43.59% and a net margin of 32.19%.

A number of other analysts also recently weighed in on the stock. Truist Financial upped their price target on shares of argenex from $1,030.00 to $1,095.00 and gave the stock a “buy” rating in a report on Tuesday. Royal Bank Of Canada upped their target price on argenex from $1,025.00 to $1,100.00 and gave the stock an “outperform” rating in a research note on Tuesday. Robert W. Baird lifted their price target on argenex from $867.00 to $932.00 and gave the company a “neutral” rating in a research note on Monday, July 27th. Wells Fargo & Company boosted their price target on argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a report on Monday, June 1st. Finally, Weiss Ratings lowered argenex from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, July 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,118.28.

argenex Stock Up 4.0%

ARGX opened at $1,032.86 on Thursday. The stock has a market capitalization of $64.62 billion, a price-to-earnings ratio of 39.66, a P/E/G ratio of 1.03 and a beta of 0.46. argenex has a twelve month low of $651.89 and a twelve month high of $1,035.09. The company has a 50-day simple moving average of $889.43 and a 200 day simple moving average of $824.32.

Institutional Investors Weigh In On argenex

A number of hedge funds and other institutional investors have recently bought and sold shares of ARGX. Navellier & Associates Inc. increased its holdings in argenex by 3.3% in the 2nd quarter. Navellier & Associates Inc. now owns 7,257 shares of the company’s stock worth $6,733,000 after purchasing an additional 234 shares in the last quarter. Merit Financial Group LLC boosted its stake in shares of argenex by 17.1% during the second quarter. Merit Financial Group LLC now owns 466 shares of the company’s stock valued at $432,000 after purchasing an additional 68 shares in the last quarter. Farther Finance Advisors LLC grew its holdings in shares of argenex by 9.6% during the second quarter. Farther Finance Advisors LLC now owns 365 shares of the company’s stock worth $338,000 after purchasing an additional 32 shares during the last quarter. Ballentine Partners LLC grew its holdings in shares of argenex by 30.8% during the second quarter. Ballentine Partners LLC now owns 772 shares of the company’s stock worth $716,000 after purchasing an additional 182 shares during the last quarter. Finally, Peregrine Capital Management LLC acquired a new position in shares of argenex in the second quarter valued at approximately $27,584,000. Institutional investors own 60.32% of the company’s stock.

Trending Headlines about argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase 3 myositis data: Vyvgart Hytrulo delivered favorable ALKIVIA trial results in autoimmune myositis, supporting a potential label expansion and reducing development risk for a significant new indication. The news helped drive a sharp advance in the shares. ARGX Announces Positive Phase III Data on Vyvgart Hytrulo
• Positive Sentiment: Analysts raised price targets: Morgan Stanley increased its target to $1,230 and kept an Overweight rating; HC Wainwright raised its target to $1,202 with a Buy rating; Wedbush lifted its target to $1,150; and Citizens JMP raised its target to $1,200. Citi also initiated or reiterated a Buy rating. These targets imply additional upside and indicate growing confidence in argenx’s commercial and pipeline outlook. HC Wainwright Boosts argenx Price Target Wedbush Raises argenx Price Target Morgan Stanley Raises argenx Price Target
• Positive Sentiment: Long-term earnings expectations improved: HC Wainwright raised its FY2029 EPS forecast to $56.38 from $53.47 and its FY2030 forecast to $76.63 from $64.39. The revisions suggest analysts expect stronger Vyvgart sales and greater earnings leverage over time.
• Neutral Sentiment: argenx SE’s shares have reached a new one-year high, reflecting strong momentum, but the stock’s elevated valuation—approximately 40 times earnings—leaves it sensitive to execution, regulatory, and commercialization risks. argenx Hits New 1-Year High

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.